Long-term impact of primary prophylaxis on joint status in patients with severe hemophilia A

Authors: Meijón Ortigueira, María Del Mar; Álvarez-Román, MT; De La Corte Rodríguez, Hortensia; Butta Coll, N; Jiménez-Yuste, V

Affiliations: Department of Hematology, Ramon y Cajal Hospital-IRYCIS, Madrid, Spain. Department of Hematology, La Paz University Hospital-IdiPAZ, Madrid, Spain. Department of Physical Medicine and Rehabilitation, La Paz University Hospital-IdiPAZ, Madrid, Spain. Res

Publication: Pract Thromb Haemost ; 2023 ; 7. 100005

Abstract: BACKGROUND: Primary prophylaxis with factor VIII concentrates is the therapeutic gold standard for severe hemophilia A. Although this approach will change substantially with the use of nonsubstitutive therapies, the long-term effects of primary prophylaxis remain unclear. We present information on joint health with tailored primary prophylaxis in a consecutive series at a single center. METHODS: We retrospectively analyzed 60 patients who did not develop early inhibitors. The annual bleeding rate and annual joint bleeding rate, prophylaxis characteristics, physical activity, adherence, and development of inhibitors were compared between those with and without joint involvement at the end of follow-up. Joint involvement was defined as a Hemophilia Joint Health Score or Hemophilia Early Arthropathy Detection with an ultrasound score ≥1. RESULTS: Among 60 patients with median follow-up of 113 ± 6 months after starting prophylaxis, 76.7% had no joint involvement at the end of the follow-up. Those without joint involvement started prophylaxis at a younger median age (1 [IQR 1-1] year vs 3 [IQR 2-4.3] years). They also had lower annual joint bleeding rate (0.0 [IQR 0-0.2] vs 0.2 [IQR 0.1-0.5]), were more often physically active (70% vs 50%) and had lower trough factor VIII levels. Adherence to treatment was not significantly different between groups. CONCLUSION: Initiation of primary prophylaxis at a younger age was the main factor associated with long-term preservation of joint status in patients with severe hemophilia A.